- Public Comps
- Allurion
Allurion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Allurion and similar public comparables like ScandiDos, Work Medical Technology Group, Spineway, Kontigo Care and more.
Allurion Overview
About Allurion
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Founded
2023
HQ

Employees
137
Website
Financials (FY)
EV
$29M
Valuation Multiples
Start free trialAllurion Financials
Allurion reported last fiscal year revenue of $15M and negative EBITDA of ($28M).
In the same fiscal year, Allurion generated $10M in gross profit, ($28M) in EBITDA losses, and had net loss of ($29M).
Revenue (LTM)
Allurion P&L
In the most recent fiscal year, Allurion reported revenue of $15M and EBITDA of ($28M).
Allurion is unprofitable as of last fiscal year, with gross margin of 63%, EBITDA margin of (182%), and net margin of (189%).
Financial data powered by Morningstar, Inc.
Allurion Stock Performance
Allurion has current market cap of $5M, and enterprise value of $29M.
Market Cap Evolution
Allurion's stock price is $4.98.
Allurion share price increased by 24.5% in the last 30 days, and by 86.2% in the last year.
Allurion has an EPS (earnings per share) of $-28.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29M | $5M | -0.4% | 24.5% | 638.6% | 86.2% | $-28.74 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAllurion Valuation Multiples
Allurion trades at 1.9x EV/Revenue multiple, and (1.1x) EV/EBITDA.
EV / Revenue (LTM)
Allurion Financial Valuation Multiples
As of July 18, 2026, Allurion has market cap of $5M and EV of $29M.
Allurion has a P/E ratio of (0.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Allurion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Allurion Margins & Growth Rates
In the most recent fiscal year, Allurion reported gross margin of 63%, EBITDA margin of (182%), and net margin of (189%).
Allurion Margins
Allurion Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Allurion Operational KPIs
Allurion's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Allurion Competitors
Allurion competitors include ScandiDos, Work Medical Technology Group, Spineway, Kontigo Care, Neola Medical, Inventionmed, Aino Health, SpectraCure, Sds Optic and Phase Holographic.
Most Allurion public comparables operate across Medical Devices, Health Data & Analytics, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.8x | - | (63.3x) | - | |||
| 0.7x | - | 20.7x | - | |||
| 0.2x | 0.2x | (3.7x) | (1.9x) | |||
| 1.3x | - | 10.3x | - | |||
| 4.1x | 3.9x | (3.9x) | (2.9x) | |||
| 7.5x | - | 13.7x | - | |||
| 1.6x | - | (17.7x) | - | |||
| - | - | (1.0x) | - | |||
This data is available for Pro users. Sign up to see all Allurion competitors and their valuation data. Start Free Trial | ||||||
Allurion VC Funding History
Before going public, Allurion raised $123M in total equity funding, across 7 rounds.
Allurion Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Allurion
| When was Allurion founded? | Allurion was founded in 2023. |
| Where is Allurion headquartered? | Allurion is headquartered in United States. |
| How many employees does Allurion have? | As of today, Allurion has over 137 employees. |
| Who is the CEO of Allurion? | Allurion's CEO is Shantanu Gaur. |
| Is Allurion publicly listed? | Yes, Allurion is a public company listed on OTCM. |
| What is the stock symbol of Allurion? | Allurion trades under ALURD ticker. |
| When did Allurion go public? | Allurion went public in 2023. |
| Who are competitors of Allurion? | Allurion main competitors include ScandiDos, Work Medical Technology Group, Spineway, Kontigo Care, Neola Medical, Inventionmed, Aino Health, SpectraCure, Sds Optic, Phase Holographic. |
| What is the current market cap of Allurion? | Allurion's current market cap is $5M. |
| What is the current revenue of Allurion? | Allurion's last fiscal year revenue is $15M. |
| What is the current EV/Revenue multiple of Allurion? | Current revenue multiple of Allurion is 1.9x. |
| Is Allurion profitable? | No, Allurion is not profitable. |
| How many companies Allurion has acquired to date? | Allurion hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Allurion has invested to date? | Allurion hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Allurion
Lists including Allurion
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




